|Systematic (IUPAC) name|
|AHFS/Drugs.com||International Drug Names|
|Molar mass||303.17 g/mol|
Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy. The complex consists of two ammine ligands and the dianion derived from glycolic acid.
Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.
- Apps, M. G., Choi, E. H. Y., Wheate, N. J. (2015). "The state-of-play and future of platinum drugs". Endocrine-related Cancer. 22 (4): 219–233. doi:10.1530/ERC-15-0237. PMID 26113607.
- Johnstone, Timothy C.; Park, Ga Young; Lippard, Stephen J. (2014-01-01). "Understanding and Improving Platinum Anticancer Drugs – Phenanthriplatin". Anticancer research. 34 (1): 471–476. ISSN 0250-7005. PMC . PMID 24403503.
- (Japanese) Aqupla アクプラ (PDF) Shionogi & Co. March 2007.
- (Japanese) Official Shionogi & Co. Website
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|